Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
We are advising consumers that Artri Ajo King tablets may pose a serious risk to your health and should not be taken.
-
GlaxoSmithKline (GSK) Australia Pty Ltd is issuing a product correction for certain batches of their Flixotide and Pavtide Accuhalers as a small number of Accuhalers may not automatically reload the next dose.
-
We are concerned about the rise in the import, supply, compounding and advertising of unapproved peptide products and the potential safety risks associated with these goods.
Latest articles
-
Three Victorians arrested following seizure of over $2 million worth of steroids and peptides by the ABF and TGA
Two Victorian men and one woman have been charged following a joint investigation into an alleged criminal syndicate importing Performance and Image Enhancing Drugs (PIEDs) into Australia. -
Stakeholders to be consulted on proposal to remove Andrographis paniculata as a low-risk ingredient
The TGA has begun consultation on a proposal to remove Andrographis paniculata (Andrographis) from the list of permitted ingredients in listed medicines. -
Product Information safety updates - March 2026
Information for health professionals about medicines with safety related updates to their Product Information.
Latest publications
-
Find out about the seasonal influenza vaccines available for the 2026 southern hemisphere season.
-
Advisory Committee on Vaccines meeting statement 54
-
Communique from the 11th meeting of the Women's Health Products Working Group, 30 October 2025